Filing Details

Accession Number:
0000899243-17-021595
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-07 16:05:44
Reporting Period:
2017-09-05
Accepted Time:
2017-09-07 16:05:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631650 Aimmune Therapeutics Inc. AIMT Pharmaceutical Preparations (2834) 452748244
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1664251 E. Susan Barrowcliffe Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300
Brisbane CA 94005-1884
General Manager, Europe No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2017-09-05 3,223 $3.02 3,223 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2017-09-05 3,223 $22.00 0 No 4 S Direct
Common Stock, $0.0001 Par Value Acquisiton 2017-09-06 15,167 $3.02 15,167 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2017-09-06 15,167 $22.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option(right to buy) Disposition 2017-09-05 3,223 $0.00 3,223 $3.02
Common Stock Stock Option(right to buy) Disposition 2017-09-06 15,167 $0.00 15,167 $3.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
203,567 2025-05-13 No 4 M Direct
188,400 2025-05-13 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $22.00 to $22.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.